Adaptimmune Therapeutics plc

Historical 13F Holders

Symbol
ADAPY
CUSIP
00653A107
All holders as of
Q1 2026
Type
Equity
Class
SPONDS ADR
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 00653A107 since 12/18/2024, largest first.

Filer % of Class Filed
Under 5%, checked the "5 percent or less" box, or amended by a later filing (6)
Baillie Gifford & Co 13G/A 4.6% 2/12/2025
Event 12/31/2024
EcoR1 Capital, LLC 13G/A
4.2% 8/19/2025
Event 8/15/2025
New Enterprise Associates 14, L.P. 13D/A
0% 8/19/2025
Event 8/15/2025
Long Focus Capital Management, LLC 13G
0% 2/17/2026
Event 12/31/2025
Matrix Capital Management Company, LP 13G/A
0% 1/8/2025
Event 12/31/2024
Two Seas Capital LP 13G/A
0% 11/14/2025
Event 9/30/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q1 1 3.66 k $72.00
2025 Q4 12 2.09 M $91.0 k
2025 Q3 58 42.1 M $5.47 M
2025 Q2 67 116 M $27.7 M
2025 Q1 72 116 M $22.9 M
2024 Q4 84 124 M $67.0 M
2024 Q3 86 153 M $145 M
2024 Q2 83 155 M $151 M
2024 Q1 87 164 M $259 M
2023 Q4 83 146 M $116 M
2023 Q3 81 148 M $116 M
2023 Q2 92 145 M $134 M
2023 Q1 68 116 M $126 M
2022 Q4 73 114 M $167 M
2022 Q3 71 114 M $122 M
2022 Q2 80 115 M $195 M
2022 Q1 84 110 M $229 M
2021 Q4 93 114 M $426 M
2021 Q3 101 112 M $577 M
2021 Q2 90 112 M $476 M
2021 Q1 91 117 M $624 M
2020 Q4 97 118 M $638 M
2020 Q3 87 130 M $1.04 B
2020 Q2 90 128 M $1.28 B
2020 Q1 52 93.8 M $255 M
2019 Q4 45 65.0 M $78.0 M
2019 Q3 51 68.1 M $103 M
2019 Q2 60 68.2 M $274 M
2019 Q1 69 69.4 M $299 M
2018 Q4 85 69.2 M $398 M
2018 Q3 102 65.5 M $888 M
2018 Q2 94 56.0 M $665 M
2018 Q1 82 56.5 M $634 M
2017 Q4 73 52.1 M $348 M
2017 Q3 70 50.8 M $416 M
2017 Q2 56 48.1 M $216 M
2017 Q1 51 39.8 M $219 M
2016 Q4 40 29.8 M $121 M
2016 Q3 47 31.1 M $219 M
2016 Q2 47 31.9 M $260 M
2016 Q1 49 32.0 M $260 M
2015 Q4 50 20.8 M $250 M
2015 Q3 41 15.2 M $181 M
2015 Q2 45 21.0 M $384 M